As for clinical characteristics, compared with the ATAb (–) group, the ATAb (+) group had higher rates of movement disorders (88.9 vs. 45.8%, p < 0.01) and sleep disorders (85.2 vs. 58.3%, p = 0.03), ANA positivity (29.6 vs. 4.1%, p = 0.03), and IVIG treatment ≥2 courses (77.8 vs. 45.8%, p = 0.02). The gene discussed is BTG3; the disease is sleep disorder.